

T9-207-T025

Monoclonal Antibody to CD8 PerCP-Cy™5.5 conjugated (25 tests)

| Clone: | MEM-31 |
|---------------------------|--|
| Isotype: | Mouse IgG2a |
| Specificity: | The antibody MEM-31 recognizes a conformationally-dependent epitope of CD8, a cell surface glycoprotein found on most cytotoxic T lymphocytes that mediates efficient cell-cell interactions within the immune system. CD8 is a disulfide-linked dimer and exists as a CD8 alpha/alpha homodimer or CD8 alpha/beta heterodimer (each monomer approx. 32-34 kDa). The antibody does not react with formaldehyde-fixed cells; negative in Western Blotting application. HLDA III; WS Code T 575 |
| Regulatory Status: | RUO |
| Immunogen: | Crude thymus membrane fraction. |
| Species Reactivity: | Human |
| Preparation: | The purified antibody is conjugated with tandem dye PerCP-Cy™5.5 under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary. |
| Storage Buffer: | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide. |
| Storage / Stability: | Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label. |
| Usage: | The reagent is designed for Flow Cytometry analysis of human blood cells using 4 μ l reagent / 100 μ l of whole blood or 10 ⁶ cells in a suspension. The content of a vial (0.1 ml) is sufficient for 25 tests. |
| Expiration: | See vial label |
| Lot Number: | See vial label |
| Background: | The CD8 T cell coreceptor (monomer approx. 32-34 kDa) is expressed as alpha/beta heterodimer on majority of MHC I-restricted conventional T cells and thymocytes and as alpha/alpha homodimer on subsets of memory T cells, intraepithelial lymphocytes, NK cells and dendritic cells. Regulation of CD8 beta level on T cell surface seems to be an important mechanism to control their effector function. Assembly of CD8 alpha-beta but not alpha-alpha dimers is connected with formation or localization to the lipid rafts. Recruiting triggered TCR complexes to these membrane microdomains as well as affinity of TCR to MHC I is modulated by CD8, thereby affecting the functional diversity of the TCR signaling. |

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz



Antibodies

References:

*Devine L, Thakral D, Nag S, Dobbins J, Hodsdon ME, Kavathas PB: Mapping the binding site on CD8 beta for MHC class I reveals mutants with enhanced binding. J Immunol. 2006 Sep 15;177(6):3930-8.

*Pang DJ, Hayday AC, Bijlmakers MJ.: CD8 Raft localization is induced by its assembly into CD8alpha beta heterodimers, Not CD8alpha alpha homodimers. J Biol Chem. 2007 May 4;282(18):13884-94.

*van den Berg HA, Wooldridge L, Laugel B, Sewell AK: Coreceptor CD8-driven modulation of T cell antigen receptor specificity. J Theor Biol. 2007 Nov 21;249(2):395-408.

*Horejsi V et al.: Monoclonal antibodies against human leucocyte antigens. I. Antibodies against beta-2-microglobulin, immunoglobulin kappa light chains, HLA-DR-like antigens, T8 antigen, T1 antigen, a monocyte antigen, and a pan-leucocyte antigen. Folia Biol. (Praha) 32, 12 (1986).

*Leukocyte Typing III., McMichael A. J. et al (Eds.), Oxford University Press (1987).

*Horejsí V, Angelisová P, Bazil V, Kristofová H, Stoyanov S, Stefanová I, Hausner P, Vosecký M, Hilgert I: Monoclonal antibodies against human leucocyte antigens.

II. Antibodies against CD45 (T200), CD3 (T3), CD43, CD10 (CALLA), transferrin receptor (T9), a novel broadly expressed 18-kDa antigen (MEM-43) and a novel antigen of restricted expression (MEM-74). Folia Biol (Praha). 1988;34(1):23-34.

*Brdicková N, Brdicka T, Angelisová P, Horváth O, Spicka J, Hilgert I, Paces J, Simeoni L, Kliche S, Merten C, Schraven B, Horejsí V: LIME: a new membrane Raft-associated adaptor protein involved in CD4 and CD8 coreceptor signaling. J Exp Med. 2003 Nov 17;198(10):1453-62.

*Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single-molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int Immunol. 2007 May;19(5):675-84.

*Estefanía E, Flores R, Gómez-Lozano N, Aguilar H, López-Botet M, Vilches C: Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets. J Immunol. 2007 Apr 1;178(7):4402-10.

*Linnebacher M, Wienck A, Boeck I, Klar E: Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO). J Biomed Biotechnol. 2010;2010:841451.

*Kanderova V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, Hrusak O, Lund-Johansen F, Kalina T: High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016 Apr;15(4):1246-61.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

Cy[™] and CyDye[™] are registered trademarks of GE Healthcare.

For laboratory research only, not for drug, diagnostic or other use.